| pubmed-article:3021478 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3021478 | lifeskim:mentions | umls-concept:C0441472 | lld:lifeskim |
| pubmed-article:3021478 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:3021478 | lifeskim:mentions | umls-concept:C0068381 | lld:lifeskim |
| pubmed-article:3021478 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:3021478 | pubmed:dateCreated | 1986-12-11 | lld:pubmed |
| pubmed-article:3021478 | pubmed:abstractText | Naloxonazine is a relatively selective mu 1 affinity label in binding studies. Like naloxazone, naloxonazine has proven valuable in vivo in establishing a role for mu 1 sites in specific opiate actions. We now report a detailed characterization of naloxonazine's actions in mice and rats. Naloxonazine antagonized morphine analgesia for greater than 24 h without altering lethality. This prolonged action could not be easily explained by a slow rate of elimination since the terminal elimination half-life was estimated at less than 3 h. Furthermore, these actions were associated with a wash-resistant inhibition of binding lasting 24 h which was relatively selective for mu 1 sites. At a fixed morphine dose, increasing naloxonazine doses lowered peak tailflick latencies in a biphasic manner, suggesting that morphine analgesia consisted of both mu 1 (naloxonazine-sensitive) and a non-mu 1 (naloxonazine-insensitive) components. The ratio of mu 1 to non-mu 1 analgesia was greater at low morphine doses, implying that morphine activated mu 1 analgesic mechanisms with higher affinity. Our studies also emphasized that naloxonazine has reversible actions similar to those of naloxone; only its irreversible actions are relatively mu 1-selective. In addition, the selectivity of naloxonazine's irreversible actions is dose-dependent. High naloxonazine doses will irreversibly antagonize receptors other than mu 1. | lld:pubmed |
| pubmed-article:3021478 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3021478 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3021478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3021478 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3021478 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:3021478 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:3021478 | pubmed:author | pubmed-author:SimantovRR | lld:pubmed |
| pubmed-article:3021478 | pubmed:author | pubmed-author:PasternakG... | lld:pubmed |
| pubmed-article:3021478 | pubmed:author | pubmed-author:ClarkJ AJA | lld:pubmed |
| pubmed-article:3021478 | pubmed:author | pubmed-author:LingG SGS | lld:pubmed |
| pubmed-article:3021478 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3021478 | pubmed:day | 23 | lld:pubmed |
| pubmed-article:3021478 | pubmed:volume | 129 | lld:pubmed |
| pubmed-article:3021478 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3021478 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3021478 | pubmed:pagination | 33-8 | lld:pubmed |
| pubmed-article:3021478 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:meshHeading | pubmed-meshheading:3021478-... | lld:pubmed |
| pubmed-article:3021478 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3021478 | pubmed:articleTitle | Naloxonazine actions in vivo. | lld:pubmed |
| pubmed-article:3021478 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3021478 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3021478 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3021478 | lld:pubmed |
